GSK: presents first global data for Ris-Rez in extensive-stage small cell lung cancer
GSK presented global data for its investigational drug Ris-Rez in extensive-stage small cell lung cancer. The phase Ib trial showed a 61% objective response rate at the 8 mg/kg dose, with a manageable safety profile. The data will be presented at the ESMO Congress 2026 and support the ongoing phase III EMBOLD SCLC-301 study.
How this was made
The 30-second read
Why it matters
The data provide the first global evidence of activity, potentially influencing GSK's oncology pipeline valuation and investor positioning ahead of the ESMO presentation.
Market read
First‑time disclosure of positive Phase Ib results for a high‑profile ADC, likely to move GSK's stock and affect biotech sector sentiment.
What to watch
The trial size is small (n=50) and safety signals (42% grade 3+ TRAEs at 8 mg/kg) could temper enthusiasm.
Background
GSK's Ris‑Rez is an investigational B7‑H3‑targeted ADC acquired from Hansoh Pharma, now in global Phase III trials for SCLC and prostate cancer.
Ticker impact
GSK announced first global Phase Ib data for its investigational ADC Ris-Rez in extensive-stage small cell lung cancer, showing a 61% ORR at 8 mg/kg.
likely upside as market prices in the encouraging response rates
Phase Ib data are new, material and suggest potential efficacy, prompting traders to consider buying or adding to positions ahead of the upcoming Phase III read‑out.
Market effects
Strengthens the outlook for ADC platforms and may benefit peers developing B7‑H3‑targeted therapies.
Positive data from a UK‑based biotech could lift European biotech indices.
Adds optimism to the broader oncology pipeline landscape.
Counterpoint
Investors may remain cautious until Phase III results confirm efficacy and safety, given early‑stage data limitations.
Key entities
- companyGSK plc
Global biopharma announcing the trial data.
- companyHansoh Pharma
Original developer of Ris‑Rez, rights holder in China.
